Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo

SIMPLE SUMMARY: Multiple myeloma remains an incurable malignancy with the majority of patients succumbing to the disease after receiving several lines of treatment, while acquiring drug resistance. Although panobinostat, a histone deacetylase inhibitor, has long been approved for the treatment of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Savvidou, Ioanna, Khong, Tiffany, Whish, Sophie, Carmichael, Irena, Sepehrizadeh, Tara, Mithraprabhu, Sridurga, Horrigan, Stephen K., de Veer, Michael, Spencer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834319/
https://www.ncbi.nlm.nih.gov/pubmed/35159107
http://dx.doi.org/10.3390/cancers14030840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834319/
https://www.ncbi.nlm.nih.gov/pubmed/35159107
http://dx.doi.org/10.3390/cancers14030840

Ejemplares similares